FLT3 D835H

CI-VAR-00000574Explore in graph →NP_004110.2:p.Asp835HisNM_004119.2:c.2503G>CClinVar 16273 CIViC 612 rs121913488

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia4
FLT3 D835H	Gilteritinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID8517 Ba/F3 cells were transfected to express FLT3-ITD or FLT3 tyrosine kinase domain mutations. Immunoblots revealed gilteritinib IC50s of 2nM, 1.6nM, and 5nM for D835H, FLT3-ITD, and wildtype (cell line: … (full text at CIViC) PMID 27908881 · Lee et al., 2017 · Open in CIViC	civic
FLT3 D835H	Sorafenib	Predictive	C	Supports Resistance	3	accepted	EID1556 Three children with relapsed or refractory FLT3-ITD-positive AML were treated with sorafenib. FLT3 mutations were assessed before treatment and at the time of resistance. During the initiation of the … (full text at CIViC) PMID 23969938 · Baker et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
16273	Pathogenic	no assertion criteria provided	0	Acute myeloid leukemia	somatic	1	Jun 01, 2001	clinvar